Adam M. Brufsky, MD, PhD, FACP | Authors


The TBCRC049 Trial for Treating Leptomeningeal Metastases in HER2+ Breast Cancer

December 14, 2019

Adam M. Brufsky, MD, PhD, FACP, discusses the TBCRC049 trial, which looks at the safety and efficacy of the tucatinib/trastuzumab/capecitabine combination to treat leptomeningeal metastases in HER2-positive breast cancer.